TargetBeta
KAT2A
lysine acetyltransferase 2A · also GCN5, PCAF-b, GCN5L2 · Lysine acetyltransferases
2 programs in company-led studies act on KAT2A, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| KAT2A/B Inhibitor PF-07994525 | Pfizer | phase 1 | 11 running | KAT2B | the company's pipeline |
| KAT2A/KAT2B Degrader AUTX-703rule | Auron Therapeutics | phase 1 | 11 running | KAT2B | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Leukemia, Myeloid, Acute, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 2027KAT2A/KAT2B Degrader AUTX-703 · Auron Therapeutics · phase 1 · NCT06846606
- Jul 10, 2029KAT2A/B Inhibitor PF-07994525 · Pfizer · phase 1 · NCT07426757
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.